|
|
|
| The 6th mRNA Based Therapeutics Summit returns to Boston as the leading forum accelerating mRNA discoveries into scalable, clinically validated therapies. Amid rapid deal making and progress across in vivo CAR T, gene editing, and cancer immunotherapy, 300+ leaders from pharma, biotech, and regulators unite. With three scientific tracks plus new AI driven design and next gen delivery focus days, this flagship event drives innovation, partnerships, and pipeline acceleration. Learn more. |
|
|
|
| Balancing Speed And Regulation In Cell Therapy | Article | By Matt Haines, Ph.D., Kincell Bio | Rapid cell therapy development demands early planning for scalability, standardized platforms, and inspection‑ready operations to meet regulatory expectations and avoid rework in later clinical phases. |
|
|
| Characterization Of Cellular Starting Material | Webinar | Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises | Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products. |
|
|
| Synthetic DNA As An Alternative For Scalable Viral Vector Production | White Paper | By Cindy Muralles, Kyle Sylakowski, Chad C. MacArthur, et al., Touchlight | Enzymatically synthesized DNA is assessed as a plasmid alternative, showing comparable viral vector yield, quality, and purification, while improving scalability and regulatory flexibility. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Sometimes, you have to go it alone. For a while, at least. The mantra across biotech has long been clear: engage your CDMO early, and let those experts guide you into manufacturing. Matthieu de Kalbermatten, CEO of CellProthera, a regenerative cell-therapy developer, begs to differ. | |
|
|
|
Forget Tech Transfer. You Need A Cognitive Connection | By Louis Garguilo, chief editor, Outsourced Pharma | Cognitive transfer is a concept widely studied in psychology. Today it has growing relevance within our industry’s ever-increasing technology transfers, which have been understood in the main as moving development/manufacturing processes/technologies from one stage, one location, or one organization – as when utilizing CDMOs – to another. Time now to zero in on the communicating of tacit or implicit knowledge, i.e., knowledge or experience difficult to extract through data or written explanation. This is where cognitive transfer enters our portal. Here's an analysis. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
| Myths That Make Early CDMO Engagement Look Like A Risk | Article | By Artur Padzik, 3PBIOVIAN | Early CDMO engagement isn’t premature—it prevents CMC-driven delays, reduces comparability risk, and aligns AAV manufacturing decisions with long-term clinical and commercial success. |
|
|
|
| Boosting Plasmid Yield & Integrity With PowerS-ITR | Poster | By Shrey Amin, Ssempa Kisaalita, Sneha Vilayur, et al., ProBio | Our platform boosts plasmid DNA yield, preserves ITR integrity, and reduces variability, enabling scalable, cost-effective manufacturing for gene therapy and vaccine applications. |
|
|
|
|
|
|
| CDMO Trends Impacting 2025-2026 | Q&A | Vector BioMed | Economic pressures, funding shifts, and evolving therapeutic pipelines are reshaping CDMO capacity in 2025, with 2026 expected to bring intensified competition and strategic realignments. |
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
